Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GILEAD SCIENCES, INC. Director's Dealing 2017

Dec 5, 2017

29828_dirs_2017-12-05_6e101047-56a3-4506-ae56-83fb7c87fe25.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2017-12-01

Reporting Person: Alton Gregg H (EVP Comm&Acs ALA, Corp&Med Aff)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-12-01 Common Stock M 8625 $24.905 Acquired 70988 Direct
2017-12-01 Common Stock S 11400 $74.4593 Disposed 59588 Direct
2017-12-01 Common Stock S 3600 $75.1988 Disposed 55988 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-01 Non-qualified Stock Option (Right to Buy) $24.905 M 8625 Disposed 2019-07-29 Common Stock (8625) Direct

Footnotes

F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F2: Sale prices reported for the transaction reported here range from $73.86 to $74.82. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request

F3: Sale prices reported for the transaction reported here range from $74.88 to $75.57. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request.

F4: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.